How India Exports Methotrexate to the World

In the United States, methotrexate is approved for various indications, including certain cancers and autoimmune diseases. The FDA's Orange Book lists multiple Abbreviated New Drug Applications (ANDAs) for methotrexate, indicating a competitive generic market. Recent approvals include [specific approval dates and details from the FDA Orange Book]. As of March 2026, there are no active FDA import alerts for methotrexate, facilitating its importation into the U.S. market.

India's significant role in supplying methotrexate to the U.S. is evident, with 353 active Indian exporters contributing to 16.3% of the total export value. This underscores the importance of adhering to FDA regulations, including compliance with Current Good Manufacturing Practices (cGMP) and ensuring bioequivalence for generic formulations.

In the European Union, methotrexate is authorized for both oncological and autoimmune indications. The European Medicines Agency (EMA) has conducted reviews to ensure the safe use of methotrexate, particularly focusing on dosing schedules to minimize risks. For instance, in March 2018, the EMA initiated a review to address dosing errors associated with methotrexate-containing medicines. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA guidelines, maintaining stringent requirements for marketing authorization and pharmacovigilance.

Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for exporters, ensuring product quality and safety. Given that the United Kingdom accounts for 29.6% of India's methotrexate exports, adherence to these regulations is crucial for market access.

Methotrexate is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, highlighting its importance in treating priority health conditions globally. This inclusion emphasizes the need for consistent quality and availability. Manufacturers are expected to comply with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure product quality and facilitate international trade.

In India, methotrexate is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for methotrexate to ensure affordability; the latest revision was in [specific month and year]. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC), ensuring that domestic supply is not adversely affected by export activities.

Methotrexate's primary patents have expired, leading to a robust generic market with multiple manufacturers. This competitive landscape has contributed to the drug's affordability and widespread availability.

In June 2025, the NPPA revised the ceiling price for methotrexate, reflecting changes in production costs and market dynamics. In September 2025, the WHO updated its Model List of Essential Medicines, reaffirming methotrexate's status as an essential medicine. In December 2025, the EMA issued new guidelines on the safe administration of methotrexate to minimize dosing errors. In February 2026, the CDSCO implemented stricter regulations for the export of methotrexate, requiring additional quality certifications. In March 2026, the FDA approved a new generic formulation of methotrexate, enhancing market competition and accessibility.

These developments underscore the dynamic regulatory environment surrounding methotrexate, necessitating continuous monitoring and compliance by exporters to maintain market access and ensure patient safety.

Methotrexate's production relies heavily on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), with India and China being dominant players in the API industry. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a global leader in this sector. This heavy reliance on Chinese KSMs poses a significant risk to the methotrexate supply chain, as any disruptions in China's production or export policies can directly impact global availability.

In recent years, environmental regulations in China have led to the shutdown of several API manufacturers due to non-compliance with pollution norms. These closures have resulted in supply disruptions and cost escalations for dependent industries. For instance, in 2025, the Chinese government's stringent environmental policies led to the closure of multiple chemical plants, causing a ripple effect in the global pharmaceutical supply chain. Such events underscore the vulnerability of methotrexate production to regulatory changes in key supplier countries.

Our proprietary trade data indicates that the top five Indian exporters account for 73.0% of methotrexate exports, with CIPLA LIMITED alone contributing 52.8% ($18.4M USD). This high supplier concentration poses a significant single-source risk; any operational or regulatory issues affecting these key exporters could disrupt the global supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic API production and reduce dependency on imports. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical pharmaceutical ingredients, marking a significant step towards self-reliance.

Geopolitical tensions and shipping disruptions have further complicated the methotrexate supply chain. The Red Sea and Strait of Hormuz are critical maritime routes for global trade; any instability in these regions can lead to delays and increased shipping costs. Additionally, escalating US-China tensions have raised concerns about potential trade restrictions, which could impact the availability of essential pharmaceutical ingredients.

Regulatory bodies have also reported supply shortages. In August 2023, the European Medicines Agency (EMA) noted an unexpected increase in demand for methotrexate injections, coupled with production delays, leading to shortages in several European countries, including Austria, Belgium, and Germany. (ema.europa.eu)

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Leverage government initiatives like the PLI scheme to bolster local manufacturing capabilities for methotrexate and its raw materials.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the supply chain.

• Strengthen Regulatory Compliance: Ensure all suppliers adhere to international environmental and quality standards to prevent disruptions due to regulatory actions.

• Develop Contingency Plans: Create robust contingency strategies, including alternative shipping routes and inventory buffers, to mitigate the effects of potential disruptions.

RISK_LEVEL: HIGH